Immunologic monitoring in transplantation revisited

Current Opinion in Organ Transplantation

Volumn 17, Issue 1, 2012, Pages 26-32

  Cravedi, Paolo ^a   Heeger, Peter S ^a,b,c  

^a Renal Division   (United States)

^b Recanati Miller Transplant Institute   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

acute rejection; biomarker; ELISPOT; genomic; proteomics

Indexed keywords

BIOLOGICAL MARKER; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA ANTIBODY; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE;

ACUTE GRAFT REJECTION; CHRONIC GRAFT REJECTION; GENOMICS; GRAFT FAILURE; HEART GRAFT; HLA SYSTEM; HUMAN; KIDNEY GRAFT; MEMORY T LYMPHOCYTE; NONHUMAN; OUTCOME ASSESSMENT; PROTEOMICS; REVIEW; RISK ASSESSMENT; TRANSPLANTATION;

ACUTE DISEASE; ANIMALS; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHEMOKINES; CHRONIC DISEASE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; MONITORING, IMMUNOLOGIC; ORGAN TRANSPLANTATION; RNA, MESSENGER; TRANSCRIPTOME; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856106564     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834ee402     Document Type: Review

References (59)

1. Kaneku HK, Terasaki PI. Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin Transpl 2006; 1:1-27.
2. Muhlberger I, Perco P, Fechete R, et al. Biomarkers in renal transplantation ischemia reperfusion injury. Transplantation 2009; 88 (3 Suppl.):S14-S19.
3. Hernandez-Fuentes MP, Lechler RI. A 'biomarker signature' for tolerance in transplantation. Nat Rev Nephrol 2010; 6:606-613.
4. Bestard O, Cruzado JM, la Franquesa M, Grinyo JM. Biomarkers in renal transplantation. Curr Opin Organ Transplant 2010; 15:467-473.
5. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75:43-49. (Pubitemid 36139693)
6. Caro-Oleas JL, Gonzalez-Escribano MF, Gonzalez-Roncero FM, et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant 2011. [Epub ahead of print]
7. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7:408-415. (Pubitemid 46096334)
8. Fotheringham J, Angel C, Goodwin J, et al. Natural history of proteinuria in renal transplant recipients developing de novo human leukocyte antigen antibodies. Transplantation 2011; 91:991-996.
9. Lachmann N, Terasaki PI, Budde K, et al. Antihuman leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87:1505-1513.
10. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11:312-319.
11. Zou Y, Stastny P, Susal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357:1293-1300. (Pubitemid 47481451)
12. Smith JD, Brunner VM, Jigjidsuren S, et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am J Transplant 2009; 9:1912-1919.
13. Quiroga I, Salio M, Koo DD, et al. Expression of MHC class I-related chain B (MICB) molecules on renal transplant biopsies. Transplantation 2006; 81: 1196-1203.
14. Haque MA, Mizobuchi T, Yasufuku K, et al. Evidence for immune responses to a self-antigen in lung transplantation: Role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002; 169:1542-1549. (Pubitemid 34809201)
15. Nath DS, Ilias Basha H, Tiriveedhi V, et al. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2010; 29:1277-1285.
16. Kalache S, Dinavahi R, Pinney S, et al. Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients. J Immunol 2011; 187:1023-1030.
17. Morgun A, Shulzhenko N, Unterkircher CS, et al. Pre and posttransplant antimyosin and antiheat shock protein antibodies and cardiac transplant outcome. J Heart Lung Transplant 2004; 23:204-209. (Pubitemid 38175298)
18. Sun Q, Cheng Z, Cheng D, et al. De novo development of circulating antiendothelial cell antibodies rather than preexisting antibodies is associated with posttransplant allograft rejection. Kidney Int 2011; 79:655-662.
19. Sutherland SM, Li L, Sigdel TK, et al. Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Kidney Int 2009; 76:1277-1283.
20. Dinavahi R, George A, Tretin A, et al. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol 2011; 22:1168-1178.
21. Page AJ, Ford ML, Kirk AD. Memory T-cell-specific therapeutics in organ transplantation. Curr Opin Organ Transplant 2009; 14:643-649.
22. Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 2009; 9:153-161.
23. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5:465-474. (Pubitemid 40313337)
24. Dinavahi R, Heeger PS. T-cell immune monitoring in organ transplantation. Curr Opin Organ Transplant 2008; 13:419-424.
25. Augustine JJ, Poggio ED, Heeger PS, Hricik DE. Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation 2008; 86:529-534.
26. Cherkassky L, Lanning M, Lalli PN, et al. Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker. Am J Transplant 2011; 11:1388-1396.
27. Gurkan S, Luan Y, Dhillon N, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010; 10:2132-2141.
28. Hartono C, Muthukumar T, Suthanthiran M. Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant 2010; 15:35-41.
29. Afaneh C, Muthukumar T, Lubetzky M, et al. Urinary cell levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and acute rejection of human renal allografts. Transplantation 2010; 90:1381-1387.
30. Suthanthiran M, Ding R, Sharma V, et al. Urinary cell messenger RNA expression signatures anticipate acute cellular rejection: A report from CTOT-04. Am J Transplant 2011; 11 (Suppl. s2):29.
31. Van Ham SM, Heutinck KM, Jorritsma T, et al. Urinary granzyme A mRNA is a biomarker to diagnose subclinical and acute cellular rejection in kidney transplant recipients. Kidney Int 2010; 78:1033-1040.
32. Lorenzen JM, Volkmann I, Fiedler J, et al. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients. Am J Transplant 2011; 11:2221-2227.
33. Schnickel GT, Bastani S, Hsieh GR, et al. Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. J Immunol 2008; 180:4714-4721.
34. Fischereder M, Schroppel B. The role of chemokines in acute renal allograft rejection and chronic allograft injury. Front Biosci 2009; 14: 1807-1814.
35. Hu H, Aizenstein BD, Puchalski A, et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4:432-437 (Pubitemid 38282301)
36. Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011; 11:2228-2234.
37. Ho J, Rush DN, Gibson IW, et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 2010; 90:394-400.
38. Mannon RB. Immune monitoring and biomarkers to predict chronic allograft dysfunction. Kidney Int Suppl 2010; 119:S59-S65.
39. Koestenbauer S, Stiegler P, Stadlbauer V, et al. Myeloperoxidase and carbonyl proteins: Promising markers for noninvasive monitoring of graft rejection after heart transplantation. J Heart Lung Transplant 2010; 29:1352-1357.
40. Haberman B, Doan ML, Smith EO, et al. Serum KL-6 level and the development of bronchiolitis obliterans syndrome in lung transplant recipients. Pediatr Transplant 2010; 14:903-908.
41. Wang D, Wu WZ, Chen JH, et al. Pretransplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal transplant recipients. Transpl Immunol 2010; 22:115-120.
42. Pavlova Y, Viklicky O, Slatinska J, et al. Soluble CD30 and hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft. Transpl Immunol 2011; 25:72-76.
43. Halim MA, Al-Otaibi T, Al-Muzairai I, et al. Serial soluble CD30 measurements as a predictor of kidney graft outcome. Transplant Proc 2010; 42:801-803.
44. Kovac J, Arnol M, Vidan Jeras B, et al. Pretransplant soluble CD30 serum concentration does not affect kidney graft outcomes 3 years after transplantation. Transplant Proc 2010; 42:4043-4046.
45. Heidt S, Shankar S, Muthusamy AS, et al. Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy. Transplantation 2011; 91:e59-e61.
46. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104:15448-15453. (Pubitemid 47502937)
47. Sarwal MM, Benjamin J, Butte AJ, et al. Transplantomics and biomarkers in organ transplantation: A report from the first international conference. Transplantation 2011; 91:379-382.
48. Einecke G, Reeve J, Sis B, et al. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest 2010; 120:1862-1872.
49. Chen R, Sigdel TK, Li L, et al. Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLoS Comput Biol 2010; 6:1-12.
50. Kurian SM, Heilman R, Mondala TS, et al. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One 2009; 4:e6212.
51. Snyder TM, Khush KK, Valantine HA, Quake SR. Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci USA 2011; 108:6229-6634.
52. Quintana LF, Sole-Gonzalez A, Kalko SG, et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 2009; 20:428-435.
53. Freue GV, Sasaki M, Meredith A, et al. Proteomic signatures in plasma during early acute renal allograft rejection. Mol Cell Proteomics 2010; 9:1954-1967
54. Nakorchevsky A, Hewel JA, Kurian SM, et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J Am Soc Nephrol 2010; 21:362-373.
55. Kobashigawa JA, Kiyosaki KK, Patel JK, et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J Heart Lung Transplant 2010; 29:504-508.
56. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006; 82:663-668. (Pubitemid 44395237)
57. Torio A, Fernandez EJ, Montes-Ares O, et al. Lack of association of immune cell function test with rejection in kidney transplantation. Transplant Proc 2011; 43:2168-2170.
58. Huskey J, Gralla J, Wiseman AC. Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. Clin J Am Soc Nephrol 2011; 6:423-429.
59. Ravaioli M, Morelli MC, Zanello M, et al. Immunosuppression monitoring by Cylex Immuknow test after liver transplantation. Preliminary results of randomized prospective trial. Abstract presented at the 2011 joint international congress of ILTS, ELITA, and LICAGE; Valencia, Spain; 22-25 June 2011.